WT1 TCR T cell therapy (Cell Medica)

N/A

Report date: 2023/05/01 20:00:20

Base Information

Drug NameWT1 TCR T cell therapy (Cell Medica)

Drug Alias NameCMD-602

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionImmunostimulantsImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumGermanyUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity College London Cell Medica Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity College London Cell Medica Ltd

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A